Literature DB >> 15928980

Tularemia vaccine: past, present and future.

Petra C F Oyston1, Janine E Quarry.   

Abstract

Francisella tularensis is a Gram negative intracellular pathogen that causes the highly debilitating or fatal disease tularemia. F. tularensis can infect a wide range of animals and can be transmitted to humans in a variety of ways, the most common being by the bite of an infected insect or arthropod vector. The attenuated F. tularensis live vaccine strain (LVS) has been used previously under investigational new drug status to vaccinate at-risk individuals. However the history of the strain and lack of knowledge regarding the basis of attenuation has so far prevented its licensing. Therefore the focus of current research is on producing a new vaccine against tularemia that would be suitable for licensing.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15928980     DOI: 10.1007/s10482-004-6251-7

Source DB:  PubMed          Journal:  Antonie Van Leeuwenhoek        ISSN: 0003-6072            Impact factor:   2.271


  29 in total

1.  Multiple mechanisms of NADPH oxidase inhibition by type A and type B Francisella tularensis.

Authors:  Ramona L McCaffrey; Justin T Schwartz; Stephen R Lindemann; Jessica G Moreland; Blake W Buchan; Bradley D Jones; Lee-Ann H Allen
Journal:  J Leukoc Biol       Date:  2010-07-07       Impact factor: 4.962

Review 2.  Tetratricopeptide repeat motifs in the world of bacterial pathogens: role in virulence mechanisms.

Authors:  Lukas Cerveny; Adela Straskova; Vera Dankova; Anetta Hartlova; Martina Ceckova; Frantisek Staud; Jiri Stulik
Journal:  Infect Immun       Date:  2012-12-21       Impact factor: 3.441

3.  Invasion of erythrocytes by Francisella tularensis.

Authors:  Joseph Horzempa; Dawn M O'Dee; Donna Beer Stolz; Jonathan M Franks; Doris Clay; Gerard J Nau
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

4.  Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.

Authors:  Heather J Ray; Yu Cong; Ashlesh K Murthy; Dale M Selby; Karl E Klose; Jeffrey R Barker; M Neal Guentzel; Bernard P Arulanandam
Journal:  Clin Vaccine Immunol       Date:  2009-02-11

5.  Bronchus-associated lymphoid tissue (BALT) and survival in a vaccine mouse model of tularemia.

Authors:  Damiana Chiavolini; Javier Rangel-Moreno; Gretchen Berg; Kate Christian; Laura Oliveira-Nascimento; Susan Weir; Joseph Alroy; Troy D Randall; Lee M Wetzler
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

6.  Immunoproteomics analysis of the murine antibody response to vaccination with an improved Francisella tularensis live vaccine strain (LVS).

Authors:  Susan M Twine; Mireille D Petit; Kelly M Fulton; Robert V House; J Wayne Conlan
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

Review 7.  Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development.

Authors:  Roger D Pechous; Travis R McCarthy; Thomas C Zahrt
Journal:  Microbiol Mol Biol Rev       Date:  2009-12       Impact factor: 11.056

Review 8.  Vaccines against tularemia.

Authors:  Eileen M Barry; Leah E Cole; Araceli E Santiago
Journal:  Hum Vaccin       Date:  2009-12-11

9.  Diverse myeloid and lymphoid cell subpopulations produce gamma interferon during early innate immune responses to Francisella tularensis live vaccine strain.

Authors:  Roberto De Pascalis; Betsy C Taylor; Karen L Elkins
Journal:  Infect Immun       Date:  2008-06-23       Impact factor: 3.441

Review 10.  The structure and function of Francisella lipopolysaccharide.

Authors:  John S Gunn; Robert K Ernst
Journal:  Ann N Y Acad Sci       Date:  2007-03-29       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.